Advice

in the absence of a submission from the holder of the marketing authorisation:

ibrutinib (Imbruvica®) is not recommended for use within NHS Scotland.

Indication under review: As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
ibrutinib (Imbruvica)
SMC ID:
1289/17
Indication:
As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
13 November 2017